戻る Agenda
Comparative Effectiveness: State of the Art and Stakeholder Perspectives
Session Chair(s)
Robert W DuBois, MD, PHD
Executive Vice President and Chief Science Officer
National Pharmaceutical Council, United States
In this session, we will think through the designs and endpoints for comparative effectiveness and safety. This work is typically performed by NIH and PCORI in the US but has been proposed to CDER and CBER.
Learning Objective : Review key areas where multiple stakeholders are converging around real world evidence for effectiveness, safety and value; Discuss the importance of patient-relevant endpoints in effectiveness and safety from PCORI's perspective; Describe how changing regulations may impact health technology assessment.
Speaker(s)
Mind the ‘Efficacy-Effectiveness’ Gap: Will Changes in Regulations on Real-World Research Revolutionize Health Technology Assessment?
David Thompson, PHD
Rubidoux Research LLC, United States
Founder and Principal Consultant
Update From PCORI
Jean Slutsky, MPH
Patient-Centered Outcomes Research Institute (PCORI), United States
Senior Advisor to the Executive Director